NanoZymeX

About NanoZymeX

NanoZymeX is a nanobiotechnology startup developing next-generation enzyme replacement therapies using proprietary lipid-based nanoparticles. Originating from research at the University of Basel, the company aims to improve intracellular delivery and reduce immunogenicity of therapeutic enzymes to treat rare genetic lysosomal storage diseases, with Pompe disease as a lead indication. Its platform delivers enzymes into target tissues via endocytic pathways independent of mannose-6-phosphate receptors, releasing active enzyme inside lysosomes for enhanced substrate clearance. The focus is on scalable, delivery-driven therapies that could expand to multiple enzymes and diseases beyond Pompe.